Join
Live feed
·
PRReleasevia Quantisnow
Ligand Pharmaceuticals Incorporated logo
Travere Therapeutics Inc. logo

Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

ByQuantisnow·Wall Street's wire, on your screen.
LGND· Ligand Pharmaceuticals IncorporatedTVTX· Travere Therapeutics Inc.
Health Care
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy | Quantisnow